Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Inclusion Criteria:

• No evidence of extrahepatic disease

• Disease not amenable to curative surgery or transplantation or curative ablation butdisease amenable to TACE

• Child Pugh score class A

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment

• Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria

• Adequate organ and marrow function

Exclusion Criteria:

• History of symptomatic congestive heart failure, unstable angina pectoris,uncontrolled cardia arrhythmia

• History of hepatic encephalopathy

• Major portal vein thrombosis visible on baseline imaging

• Uncontrolled arterial hypertension

• Co-infection with HBV and HDV